Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0363220100480060513
Korean Journal of Dermatology
2010 Volume.48 No. 6 p.513 ~ p.516
Psoriasis Aggravated by Adalimumab: A Paradoxical Adverse Reaction
Park Oun-Jae

In Seung-Gyun
Kang Seong-Min
Hong Seung-Phil
Bak Ha-Na
Won Chong-Hyun
Chang Sung-Eun
Lee Mi-Woo
Choi Jee-Ho
Moon Kee-Chan
Abstract
Adalimumab, a recombinant human IgG monoclonal antibody, selectively blocks tumor necrosis factor-alpha (TNF- ¥á) and has been successfully used in the treatment of immune-mediated diseases. In particular, its efficacy has been proven in the treatment of rheumatoid arthritis, spondylarthritis, lymphoproliferative diseases and inflammatory bowel disease. Its use has also been studied for the treatment of psoriasis and yet, paradoxically, cases of new onset or exacerbation of psoriasis continue to increase in patients undergoing treatment with anti TNF-¥á agents. A 51-year-old woman had arthritis for a year and was diagnosed with psoriatic arthritis. After she had received adalimumab for psoriatic arthritis five times during one year, erythematous eruptions were found on her entire body. She then stopped adalimumab therapy for two months, although her skin lesions did not resolve. The patient was diagnosed with psoriasis through biopsy and began using cyclosporine, a topical steroid used for treatment of psoriasis. (Korean J Dermatol 2010;48(6):513¡­516)
KEYWORD
Adalimumab, Psoriasis, Tumor necrosis factor
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø